March 30, 2023 08:00 ET – Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety […]
La teleconferencia se celebrará el jueves 30 de marzo a las 8:30 a.m. ET March 25, 2023 12:51 ET ROCKVILLE, Maryland, March 25, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), una empresa diversificada en fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de importantes necesidades no
Conference call to be held on Thursday, March 30 at 8:30 a.m. ET March 24, 2023 16:05 ET ROCKVILLE, Md., March 24, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans
March 20, 2023 08:00 ET ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 27, 2023, at 8:30 a.m.
March 20, 2023 08:00 ET ROCKVILLE, Maryland, March 20, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que tiene previsto realizar una teleconferencia el lunes 27 de marzo de
February 16, 2023 12:05 ET – Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb. 16,
February 16, 2023 12:05 ET – Datos presentados en los Tandem Meetings 2023: Reuniones sobre trasplantes y terapias celulares de la ASTCT y el CIBMTR – – Los análisis de los pacientes que recibieron meropenem sugieren que SYN-004 se tolera bien con HCT y no se observó en las muestras de sangre de la mayoría
Want to learn more? We’d love to hear from you. US Headquarters 9605 Medical Center Dr. Suite 270 Rockville, MD 20850 European Office Theriva™ Biologics SL Carrer Torrent de Can Ninou, naus 5-6 08150 – Parets del Vallès (Barcelona) Spain Email info@therivabio.com
WORK AT THERIVA™ As we grow, we continue to seek talented and driven scientists, marketers, analysts, and engineers who share in our mission. We are a collaborative, generous, and committed team that is devoted to leveraging the unique perspectives of every team member in our efforts to develop first-in-class cancer therapies. While there are no
